

# Argentina

Population 2015

43 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.7 (0.67–0.73)	1.6 (1.5–1.7)
Mortality (HIV+TB only)	0.1 (<0.01–0.52)	0.24 (0–1.2)
Incidence (includes HIV+TB)	11 (9.5–13)	25 (22–29)
Incidence (HIV+TB only)	0.79 (0.61–0.99)	1.8 (1.4–2.3)
Incidence (MDR/RR-TB)**	0.53 (0.37–0.69)	1.2 (0.85–1.6)

## Estimated TB incidence by age and sex (thousands)\*, 2015

	0-14 years	> 14 years	Total
Females	0.44 (0.25–0.63)	4.4 (3.4–5.5)	4.9 (3.6–6.1)
Males	0.44 (0.3–0.59)	5.7 (4.5–7)	6.2 (4.8–7.6)
Total	0.88 (0.65–1.1)	10 (9.2–11)	11 (9.5–13)

## TB case notifications, 2015

Total cases notified	10 506
Total new and relapse	9 601
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	19%
- % pulmonary	86%
- % bacteriologically confirmed among pulmonary	70%

## Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2015	87% (75–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.07 (0.05–0.1)

## TB/HIV care in new and relapse TB patients, 2015

	Number	(%)
Patients with known HIV-status who are HIV-positive	606	34%
- on antiretroviral therapy		

Drug-resistant TB care, 2015	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			440 (300–570)
Estimated % of TB cases with MDR/RR-TB	2.3% (1.1–3.6)	18% (11–25)	
% notified tested for rifampicin resistance	8%	16%	2 283
MDR/RR-TB cases tested for resistance to second-line drugs			102
Laboratory-confirmed cases		MDR/RR-TB: 120, XDR-TB: 12	
Patients started on treatment ****		MDR/RR-TB: 110, XDR-TB: 5	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2014	52%	9 441
Previously treated cases, excluding relapse, registered in 2014	37%	1 107
HIV-positive TB cases, all types, registered in 2014	34%	468
MDR/RR-TB cases started on second-line treatment in 2013	15%	88
XDR-TB cases started on second-line treatment in 2013	0%	3

## TB preventive treatment, 2015

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

## TB financing, 2016

National TB budget (US\$ millions)	2.9
Funding source: 100% domestic, 0% international, 0% unfunded	

\* Ranges represent uncertainty intervals


\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history

\*\*\*\* Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


# Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence  
— Notified (new and relapse)  
— Incidence (HIV+TB only)

## Notified cases by age group and sex, 2015



## Treatment success rate (%)



— New and relapse  
— Retreatment, excluding relapse  
— HIV-positive — MDR/RR-TB — XDR-TB

## Total budget (US\$ millions)

